Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.
作者信息
Dykes Carrie, Mukherjee A Lisa, Bosch Ronald J, Connick Elizabeth, Volberding Paul A, Demeter Lisa M
出版信息
J Acquir Immune Defic Syndr. 2010 Sep;55(1):132-4. doi: 10.1097/QAI.0b013e3181d5a800.
Abstract
摘要
相似文献
1
Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.
J Acquir Immune Defic Syndr. 2010 Sep;55(1):132-4. doi: 10.1097/QAI.0b013e3181d5a800.
2
Therapies. Confronting the limits of success.
Science. 2002 Jun 28;296(5577):2320-4. doi: 10.1126/science.296.5577.2320.
3
[Diagnosis of resistance in the treatment of AIDS: clarification of viral and cellular factors].
Dtsch Med Wochenschr. 2001 Nov 2;126(44):1249-54. doi: 10.1055/s-2001-18136.
4
HIV/AIDS. Experts question danger of 'AIDS superbug'.
Science. 2005 Feb 25;307(5713):1185. doi: 10.1126/science.307.5713.1185.
5
Questions about HIV causing AIDS? Viral load and T-cell (CD4) counts: why they really matter.
AIDS Treat News. 2001 May 11(364):7-8.
6
AIDS therapy. Failure isn't what it used to be...but neither is success.
Science. 1998 Feb 20;279(5354):1133-4. doi: 10.1126/science.279.5354.1133.
7
Statistical advances in AIDS therapy trials.
Stat Methods Med Res. 2001 Apr;10(2):85-100. doi: 10.1177/096228020101000202.
8
[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. doi: 10.1055/s-2007-979365.
9
Advances painted in shades of gray at a D.C. conference.
Science. 1997 Jan 31;275(5300):615-6. doi: 10.1126/science.275.5300.615.
10
[Study on the correlation between HIV drug resistance and CD4+ T-lymphocyte of AIDS patients under antiretroviral treatment in Henan province].
Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Dec;29(12):1181-4.
本文引用的文献
1
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.
AIDS. 2009 Sep 24;23(15):1987-95. doi: 10.1097/QAD.0b013e32832eb285.
2
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals.
J Virol. 2009 Mar;83(6):2715-27. doi: 10.1128/JVI.01960-08. Epub 2008 Dec 30.
3
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.
J Virol. 2008 Jun;82(11):5510-8. doi: 10.1128/JVI.02579-07. Epub 2008 Mar 19.
4
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.
J Antimicrob Chemother. 2007 Jun;59(6):1047-56. doi: 10.1093/jac/dkm082. Epub 2007 Apr 19.
5
Update of the drug resistance mutations in HIV-1: Fall 2005.
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
6
The impact of the M184V substitution on drug resistance and viral fitness.
Expert Rev Anti Infect Ther. 2004 Feb;2(1):147-51. doi: 10.1586/14787210.2.1.147.
7
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.
AIDS. 2004 Aug 20;18(12):1653-60. doi: 10.1097/01.aids.0000131377.28694.04.
8
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
J Med Chem. 2004 Jul 15;47(15):3892-6. doi: 10.1021/jm031147e.
9
Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
J Virol. 2003 Jul;77(14):7736-45. doi: 10.1128/jvi.77.14.7736-7745.2003.
10
Rates of transmission of antiretroviral drug resistant strains of HIV-1.
J Clin Virol. 2003 Feb;26(2):153-61. doi: 10.1016/s1386-6532(02)00114-2.
Zotero 插件